Transforming Cancer Care with AI Precision Medicine
Ataraxis Breast
First clinically available AI-native breast cancer platform.
AI Precision Medicine
Ataraxis is developing pioneering artificial intelligence methods to integrate information from multiple digital data modalities. Through cutting-edge artificial intelligence, Ataraxis systems discover novel clinical, morphological, and molecular features of patients and their disease, which capture the heterogeneity of cancer beyond a single data type.
Our proprietary technology analyzes multi-modal patient data to assess the aggressiveness of the disease, predict risk of cancer recurrence or death, and how various treatment options can benefit different patients, for example in breast cancer through Ataraxis Breast.
All Ataraxis tests are based on AI foundation models, such as Kestrel, trained with hundreds-of-millions of pan-cancer pathology slide images, that extract novel information about tumor morphology which strongly correlate with patient outcomes and treatment response.
Unlike traditional molecular genomic tests, we deliver results of our analyses within 24 hours from the receipt of patient data. Additionally, physical tissue is not exhausted and no additional histology preparation is necessary.
Collaborators
We are actively collaborating with top international cancer centers on the development, validation, and implementation of Ataraxis technology. Some of the health systems that worked with us on clinical or research projects include:
Latest News
Browse latest news and achievements from our team, updated weekly and exclusively.